Lucerastat
Lucerastat (NBDGJ) is an orally administered glucosylceramide synthase (GCS) inhibitor investigated for Fabry disease. By blocking a key step in sphingolipid biosynthesis, it reduces the accumulation of pathogenic substrates, as demonstrated in relevant cellular and animal models of lysosomal storage disorders.
Product Specifications
CAS Number
141206-42-0
Field of Research
Metabolism Research
Purity
98.00% (May vary between batches)
Smiles
C (CCC) N1[C@H] (CO) [C@H] (O) [C@H] (O) [C@@H] (O) C1
Molecular Formula
C10H21NO4
Molecular Weight
219.28
Storage Conditions
-20°C
Notes
For research use only.
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1014967-01 0.02 mg (E-Coli)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details 
MBS1014967-02 0.02 mg (Yeast)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details MBS1014967-03 0.1 mg (E-Coli)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details MBS1014967-04 0.1 mg (Yeast)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details 
MBS1014967-05 0.02 mg (Baculovirus)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details 
MBS1014967-06 0.02 mg (Mammalian-Cell)
Recombinant Vaccinia virus DNA-directed RNA polymerase 35 kDa subunit (RPO35)
Sign In for Pricing
View Details